OOIR: Observatory of International Research

Papers

(The H4-Index of Vaccine is 45. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Syncope after live attenuated influenza vaccine: Reports to the Vaccine Adverse Event Reporting System (2003–2024)	284
Cost-effectiveness of anti-viral treatment for infants with RSV disease in the United Kingdom	184
Quantitation and characterization of serotype 6A activation for pneumococcal conjugate vaccine by cryo-EM and SEC methods	174
“Fighting the pandemic!” Western Australian pharmacists’ perspectives on COVID-19 vaccines: A qualitative study	130
Humoral immune response profile of a cattle herd vaccinated with 5- and 10-times Bakirköy strain sheep pox vaccine under field conditions	127
Reduced cell-mediated immune response in hyperglycemic NOD mice following influenza vaccination	105
Supply, then demand? Health expenditure, political leanings, cost obstacles to care, and vaccine hesitancy predict state-level COVID-19 vaccination rates	103
Cost of illness due to pertussis in adults ≥50 years of age in the United Kingdom	101
Erratum to “Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals” [Vaccine 41(37) (2023) 5469-5476]	101
BBIBP-CorV vaccine effectiveness against COVID-19 in patients aged 60 years and older during the Delta-dominant period in the Federation of Bosnia and Herzegovina, a test-negative case-control study	91
Compliance, procrastination and refusal: American COVID-19 vaccination trust and value orientation	89
Pre-implementation evaluation for an HPV vaccine provider communication intervention among primary care clinics	88
Assessing commutability of the first WHO International Standard for antiserum to respiratory syncytial virus	87
Letter to the editor: SARS-CoV-2 vaccination in children and adolescents with neurodevelopmental or psychiatric disorders	86
Nationwide rollout of HPV vaccination in Nepal: Early key insights	82
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine	81
Editorial Board/Aims and Scope	75
Editorial Board/Aims and Scope	74
Stability studies for the identification of critical process parameters for a pharmaceutical production of the Orf virus	70
Vaccination during febrile illness, what do we know? A systematic-narrative hybrid review of the literature and international recommendations	69
The Brucella abortus A19ΔfeuPΔfeuQ double-mutant is highly attenuated and confers protection in BALB/c mice	68
Advancing the use of vaccine impact modeling for immunization decisions in low- and middle-income countries	66
Examining the independent and interactive roles of intolerance of uncertainty in vaccination intent	62
Knowledge, attitudes, and practices of healthcare providers regarding vaccinating children with cancer in Latin America and the Caribbean	61
Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19 vaccinations in South Korea	61

Racial and ethnic differences among Mpox vaccination recipients by vaccination facility type in New York City—August–December 2022	61
Knowledge, attitudes, and practices regarding seasonal influenza vaccination during pregnancy in Costa Rica: A mixed-methods study	59
Corrigendum to “Recombinant BCGΔBCG1419c protects outbred mice against M. tuberculosis challenge” [Vaccine 61 (2025) 127347]	58
Identification of T-cell epitopes of the intracellular parasite Babesia bovis by immunopeptidomic analysis of BoLA-II presented peptides	58
Healthcare professional and professional stakeholders’ perspectives on vaccine mandates in Switzerland: A mixed-methods study	57
Corrigendum to “Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: A systematic review and meta-analysis” [Vaccine 40(41) (2022) 5971	57
Corrigendum to “I want to chat with a person”: a qualitative longitudinal cohort study in England exploring drivers of sub-optimal childhood vaccination uptake” [Vaccine 62 (2025) 127462]	57
UK healthcare professionals’ attitudes towards the introduction of varicella vaccine into the routine childhood vaccination schedule and their preferences for administration	56
Vaccine efficacy induced by 2020-2021 seasonal influenza-derived H3N1 virus-like particles co-expressing M2e5x or N2	55
Integrating the person-centered approach with the study of vaccine hesitancy: Applying latent profile analysis to identify vaccine hesitancy subpopulations and assess their relations with correlates a	55
Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysacchar	53
A scoping review of multicomponent interventions to improve uptake of routine childhood vaccines in low- and middle-income countries	51
Pneumococcal vaccines: A dose of change. Vaccine failures and breakthrough infections in Belgian children during the PCV13 era (2019–2024)	49
Effectiveness of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children <2 years old: A prospective population-based study in rural Bangladesh	49
COVID-19 vaccine production and the technological gap in the Global South: The cases of Argentina and Brazil	49
Pediatric otitis media in Japan: A nationwide longitudinal study of the pre- and post-pneumococcal conjugate vaccine eras born in 2001 and 2010	48
A randomized, blind, parallel controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years an	46
Social and demographic patterns of influenza vaccination coverage in Norway, influenza seasons 2014/15 to 2020/21	46
Multi-mode spatial accessibility to vaccination services and its impact on influenza-related hospitalisations among older adults	46
Vaccine financing in the Middle East and Africa: An overview from 2010 to 2019	45
IFITM3-deficient mice as a model for testing influenza virus vaccines via the intramuscular route	45